hVIVO gets HSE clearance, launches new lab services
Hvivo
16.50p
16:55 17/01/20
Specialist contract research organisation hVIVO launched the full suite of services provided by its hLAB division - a highly specialised virology and immunology laboratory supporting preclinical and clinical drug development - on Monday.
Pharmaceuticals & Biotechnology
19,430.33
16:49 21/11/24
The AIM-traded firm said that with its new facility in Canary Wharf, it had tripled hLAB's capacity, allowing the division to offer standalone laboratory services for the first time.
It had already secured three standalone contracts in 2024, including its first major field study.
hVIVO said hLAB’s expanded capabilities included the recent completion of a containment level three (CL-3) laboratory, which had received Health and Safety Executive (HSE) clearance.
The new lab would enable the company to work with hazard group three pathogens, further enhancing its virology and immunology offerings.
In addition, hLAB had broadened its assay portfolio, providing critical services for new pathogens such as omicron, human metapneumovirus (hMPV), dengue, and a wider range of influenza, RSV, and HRV strains.
The division also expanded its field trial biologistics services, enabling bespoke sample collection kits for multinational field studies.
Additionally, hLAB had launched its biobank services, approved by the UK Research Ethics Committee, creating a comprehensive repository of human biological samples to support innovation in vaccine development, immunology, and respiratory research.
At 1044 BST, shares in hVIVO were down 0.11% at 28.3p.
Reporting by Josh White for Sharecast.com.